This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1994 Feb;151(2):289.

doi: 10.1176/ajp.151.2.289.

Physical symptoms associated with paroxetine discontinuation

L C Barr, W K Goodman, L H Price

PMID: 8296907
DOI: 10.1176/ajp.151.2.289

Case Reports

Physical symptoms associated with paroxetine discontinuation

L C Barr et al. Am J Psychiatry. 1994 Feb.

. 1994 Feb;151(2):289.

doi: 10.1176/ajp.151.2.289.

Authors

L C Barr, W K Goodman, L H Price

PMID: 8296907
DOI: 10.1176/ajp.151.2.289

No abstract available

PubMed Disclaimer

Similar articles

Withdrawal after discontinuation of paroxetine.
Arya DK. Arya DK. Aust N Z J Psychiatry. 1996 Oct;30(5):702. Aust N Z J Psychiatry. 1996. PMID: 8902183 No abstract available.
Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine.
Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Keuthen NJ, et al. J Clin Psychopharmacol. 1994 Jun;14(3):206-7. doi: 10.1097/00004714-199406000-00010. J Clin Psychopharmacol. 1994. PMID: 8027419 No abstract available.
Physical symptoms associated with paroxetine withdrawal.
Debattista C, Schatzberg AF. Debattista C, et al. Am J Psychiatry. 1995 Aug;152(8):1235-4. doi: 10.1176/ajp.152.8.1235b. Am J Psychiatry. 1995. PMID: 7625481 No abstract available.
Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
Kamijima K, Aoki M. Kamijima K, et al. Expert Rev Neurother. 2006 Jul;6(7):945-56. doi: 10.1586/14737175.6.7.945. Expert Rev Neurother. 2006. PMID: 16831110 Review.
Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
Bhanji NH, Chouinard G, Kolivakis T, Margolese HC. Bhanji NH, et al. Can J Clin Pharmacol. 2006 Winter;13(1):e69-74. Epub 2006 Jan 23. Can J Clin Pharmacol. 2006. PMID: 16456219 Review.

See all similar articles

Cited by

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH, Goa KL. Foster RH, et al. CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010. CNS Drugs. 1997. PMID: 23338224
Continuous home cage monitoring of activity and sleep in mice during repeated paroxetine treatment and discontinuation.
Collins HM, Pinacho R, Tam SKE, Sharp T, Bannerman DM, Peirson SN. Collins HM, et al. Psychopharmacology (Berl). 2023 Nov;240(11):2403-2418. doi: 10.1007/s00213-023-06442-3. Epub 2023 Aug 16. Psychopharmacology (Berl). 2023. PMID: 37584734 Free PMC article.
A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature.
Clewes J. Clewes J. Prim Care Companion CNS Disord. 2012;14(1):PCC.11br01218. doi: 10.4088/PCC.11br01218. Epub 2012 Feb 16. Prim Care Companion CNS Disord. 2012. PMID: 22690352 Free PMC article.
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
Black K, Shea C, Dursun S, Kutcher S. Black K, et al. J Psychiatry Neurosci. 2000 May;25(3):255-61. J Psychiatry Neurosci. 2000. PMID: 10863885 Free PMC article. Review.
Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal.
Novak KJ, Douglas WI, Kuhn RJ. Novak KJ, et al. J Pediatr Pharmacol Ther. 2008 Jan;13(1):25-8. doi: 10.5863/1551-6776-13.1.25. J Pediatr Pharmacol Ther. 2008. PMID: 23055861 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon